NCT04400474 2025-06-19CABATENGrupo Espanol de Tumores NeuroendocrinosPhase 2 Completed93 enrolled 17 charts
NCT04579757 2025-05-08Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsHutchmedPhase 1/2 Terminated87 enrolled 29 charts